Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CHRS Relative to the S&P 500

CHRS Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Coherus BioSciences Inc. (NASD:CHRS) seasonal charts above shows that a Buy Date of June 16 and a Sell Date of September 9 has resulted in a geometric average return of 11.32% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 41.98% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an?immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue?from the United States.

To download CHRS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CHRS